The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...
SurvivorNet on MSN
Bayer’s Dr. Dominik Ruettinger on a promising new oral treatment option for patients with HER2+ lung cancer
A targeted therapy called sevabertinib has been approved for patients with non-small cell lung cancer that carries an activating mutation in the HER2 gene.
PSAT1 and PSRC1 are upregulated in SCLC, with PSRC1 linked to lower survival rates, suggesting potential therapeutic targets. COLEC12, PLLP, and HP are downregulated, affecting immune response and ...
News-Medical.Net on MSN
Why lung cancer in never smokers is rising and how targeted detection could reduce deaths
By Priyanjana Pramanik, MSc. Researchers reveal why lung cancer in people who never smoked is increasing and explore how ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — An experimental cancer treatment from Roche failed to improve ...
In the United States and elsewhere, there’s been a major shift in patients treated for lung cancer. As the percentage of ...
A research team led by Dr. Juyeon Jung at the Bio-Nano Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), has developed a nanobody-based technology that can precisely ...
Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results